Alligent is a medical affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry. The deal was supported by the Halifax Group, a private equity firm that invests in health and biopharma services businesses, partnering with the Envision management team to provide the equity investment to facilitate the acquisition.
Alligent’s core skill sets of medical strategy development and planning, allied program implementation and stakeholder support will complement Envision’s existing services of strategic data dissemination—including publication planning, consultancy and market access communications—to provide global medical affairs departments with compliant, strategically focused evidence communication programs.
Underpinning its services, the expanded Envision Pharma Group will continue to provide its expansive client base with technology including Datavision, Visiontracker, Clear and Medinfo. Alligent’s two principals, Joe Kohles and David Thompson, also will be joining the Envision Pharma Leadership team.